Krystal Biotech (KRYS) Shares Outstanding (Weighted Average) (2016 - 2026)

Krystal Biotech has disclosed Shares Outstanding (Weighted Average) across 11 years of filings, most recently posting $29.3 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $29.3 million, up 1.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.3 million (up 1.64% YoY), and the FY2025 annual result was $28.9 million, up 1.23% from the prior year.
• Shares Outstanding (Weighted Average) came in at $29.3 million for Q1 2026 at Krystal Biotech, up from $28.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $29.3 million in Q1 2026 to a low of $25.1 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $28.3 million (2024), against an average of $27.5 million.
• Across the five-year window, Shares Outstanding (Weighted Average) rose 18.17% in 2022 and rose 0.62% in 2025, its largest moves.
• Krystal Biotech's Shares Outstanding (Weighted Average) stood at $25.5 million in 2022, then climbed by 6.52% to $27.2 million in 2023, then rose by 5.3% to $28.6 million in 2024, then increased by 1.23% to $28.9 million in 2025, then climbed by 1.19% to $29.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $29.3 million (Q1 2026), $28.9 million (Q4 2025), and $28.9 million (Q3 2025), per Business Quant data.